[HTML][HTML] Immunotherapy in non-small cell lung cancer: Past, present, and future directions

SR Punekar, E Shum, CM Grello, SC Lau… - Frontiers in …, 2022 - frontiersin.org
Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

[HTML][HTML] Basis of PD1/PD-L1 therapies

B Seliger - Journal of clinical medicine, 2019 - mdpi.com
It is obvious that tumor cells have developed a number of strategies to escape immune
surveillance including an altered expression of various immune checkpoints, such as the …

[HTML][HTML] Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer

Y Shimada, J Matsubayashi, Y Kudo, S Maehara… - Scientific reports, 2021 - nature.com
PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-
small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play …

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

I Alborelli, K Leonards, SI Rothschild… - The Journal of …, 2020 - Wiley Online Library
In non‐small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly
improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive …

[HTML][HTML] 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

IC Kok, JS Hooiveld, PP van de Donk, D Giesen… - Annals of …, 2022 - Elsevier
Background Programmed cell death protein 1 (PD-1) antibody treatment is standard of care
for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients …

[HTML][HTML] Exosomal PD-L1: new insights into tumor immune escape mechanisms and therapeutic strategies

K Zhou, S Guo, F Li, Q Sun, G Liang - Frontiers in Cell and …, 2020 - frontiersin.org
As a classical immune checkpoint molecule, PD-L1 on the surface of tumor cells plays a
pivotal role in tumor immunosuppression, primarily by inhibiting the antitumor activities of T …

[HTML][HTML] Immunotherapy in non-small cell lung cancer: Update and new insights

X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of clinical and …, 2021 - ncbi.nlm.nih.gov
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels

V Endris, I Buchhalter, M Allgäuer… - … journal of cancer, 2019 - Wiley Online Library
Assessment of Tumor Mutational Burden (TMB) for response stratification of cancer patients
treated with immune checkpoint inhibitors is emerging as a new biomarker. Commonly …

[HTML][HTML] Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study

M Tiako Meyo, A Jouinot, E Giroux-Leprieur, E Fabre… - Cancers, 2020 - mdpi.com
A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-
PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 …

The clinical significance of soluble PD-1 and PD-L1 in lung cancer

TA Hejleh, M Furqan, Z Ballas, G Clamon - Critical reviews in oncology …, 2019 - Elsevier
Abstract Soluble PD-1 and PD-L1 are detected in the serum and plasma of lung cancer
patients. The significance of these soluble proteins as prognostic or predictive markers in …